Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Autor: Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia

Publikováno v: Smith, M, Rowling, E, Miskolczi, Z, Ferguson, J, Spoerri, L, Haass, N K, Sloss, O, McEntegart, S, Arozarena, I, Kriegsheim, A V, Rodriguez, J, Brunton, H, Kmarashev, J, Levesque, M P, Dummer, R, Frederick, D T, Flaherty, K T, Andrews, M, Cooper, Z A, Wargo, J A & Wellbrock, C 2017, ' Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure ', EMBO Molecular Medicine . https://doi.org/10.15252/emmm.201607156
EMBO Molecular Medicine
Smith, M P, Rowling, E J, Miskolczi, Z, Ferguson, J, Spoerri, L, Haass, N K, Sloss, O, McEntegart, S, Arozarena, I, von Kriegsheim, A, Rodriguez, J, Brunton, H, Kmarashev, J, Levesque, M P, Dummer, R, Frederick, D T, Andrews, M C, Cooper, Z A, Flaherty, K T, Wargo, J A & Wellbrock, C 2017, ' Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure ', EMBO Molecular Medicine . https://doi.org/10.15252/emmm.201607156

Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a "MITF-high" phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8cdcf444aebcef9c5474956100dbcf15
https://doi.org/10.15252/emmm.201607156